Search clinical trials for: Rebif

Total 82 results

EMD Serono

Completed

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device (RebiQoL)

Multiple Sclerosis | Relapsing-Remitting

Sweden, Germany
EMD Serono

Completed

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) (REPLAY)

Multiple Sclerosis

Italy, Russian Federation, United States, Argentina, Venezuela, Canada, Tunisia, France
EMD Serono

Withdrawn

Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands

Terminated

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) (MESTRE-MS)

Multiple Sclerosis

Germany
EMD Serono

Completed

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

Multiple Sclerosis, Relapsing-Remitting

United States
Merck KGaA, Darmstadt, Germany
EMD Serono Canada Inc.

Completed

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome (CIS-ON)

Clinically Isolated Syndrome

Canada
University of North Carolina, Chapel Hill

Completed

EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany
Merck spol.s.r.o., Czech Republic

Completed

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (SKORE)

Multiple Sclerosis, Relapsing-Remitting

Czech Republic
EMD Serono

Completed

Rebif New Formulation (RNF) Quality of Life (QOL) Study (RebiQoL)

Relapsing Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Multiple Sclerosis

Germany
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
EMD Serono
Merck Serono International SA

Completed

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Multiple Sclerosis, Relapsing-remitting
Waukesha Memorial Hospital
The Cleveland Clinic

Completed

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Relapsing-Remitting Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Biogen

Completed

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Multiple Sclerosis

United States
Washington University School of Medicine
National Institute on Disability, Independent Living, and Rehabilitation...

Active, not recruiting

Aging With Long Term Physical Disabilities

Physical Disability

United States
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Relapsing Multiple Sclerosis

United Kingdom
EMD Serono

Completed

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, Sweden
IMS HEALTH GmbH & Co. OHG
EMD Serono

Completed

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® (PROTRACT)

Relapsing-remitting Multiple Sclerosis

United States, Canada
Aaron Boster
Pfizer; EMD Serono

Completed

Combination Therapy Using Cellcept and Rebif in RRMS

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
Bayer

Completed

Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

Relapsing-remitting Multiple Sclerosis

France
Merck KGaA, Darmstadt, Germany

Completed

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (RELIEF)

Multiple Sclerosis, Relapsing-Remitting

Germany
Merck KGaA, Darmstadt, Germany

Completed

REbif FLEXible Dosing in Early Multiple Sclerosis (MS) (REFLEX)

Multiple Sclerosis

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Turkey, Estonia, Germany, Latvia, Poland, Romania, Argentina, Israel, Portugal, Greece, Czech Republic, Slovakia, Serbia, Austria, Finland, Saudi Arabia, Belgium, Canada, Lebanon and more
EMD Serono
Merck Serono International SA

Completed

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany

Completed

Transition to Rebif New Formulation (TRANSFER)

Relapsing Multiple Sclerosis

France, Germany
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
Merck KGaA, Darmstadt, Germany

Completed

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) (TOURIMS)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients (SEPTIME)

Multiple Sclerosis, Relapsing, Remitting
Merck KGaA, Darmstadt, Germany
EMD Inc., Canada

Completed

Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (MEASURE)

Multiple Sclerosis | MS

Canada
Biogen

Completed

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis (PROOF)

Multiple Sclerosis

United States, Australia, Austria, Canada
Biocad

Completed

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Healthy

Russian Federation
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease (REAL)

Alzheimer's Disease

Italy
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Relapsing-Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Relapsing Remitting Multiple Sclerosis
Brigham and Women's Hospital
EMD Serono

Withdrawn

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany

Completed

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Multiple Sclerosis

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany

Completed

Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED)

Clinically Isolated Syndrome | Relapsing Multiple Sclerosis

Germany
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany
Merck Serono Middle East FZ LLC

Completed

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Relapsing Multiple Sclerosis (RMS)

Bulgaria, Poland, Argentina, Hungary, Korea, Republic of, Saudi Arabia, Egypt, Algeria, Bahrain, Iran, Islamic Republic of, Kuwait, Lebanon, Morocco
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS I)

Multiple Sclerosis, Relapsing-Remitting

Australia, France, United States, Germany, Canada, United Kingdom, Russian Federation, Argentina, Brazil, Croatia, Poland, Serbia, Sweden, Ukraine, Czech Republic, Mexico
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
German University in Cairo

Recruiting

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Multiple Sclerosis

Egypt
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation

Search clinical trials for: Rebif

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations